Follow The Filings

Gilead Sciences, Inc.

Foster City, CA 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

  • $1.6B
  • 5 holdings
  • 2026 Q2
  • −22.1% QoQ
  • Top 5 100.0%

In 2026 Q2 Gilead Sciences added to Assembly Biosciences and sold out of Arcellx.

Portfolio

2026 Q2, filed 8/3/2026, 5 holdings

Top 5 100.0%, top 10 100.0%

  1. RCUS, Arcus Biosciences 58.8%
  2. LKFT, Lakefront Biotherapeutics 30.3%
  3. ASMB, Assembly Biosciences 8.3%
  4. Kyverna Therapeutics 2.2%
  5. Xilio Therapeutics 0.4%

AUM over time

2026 Q2 $1.6B −22.1% QoQ
2025 Q3: $1.8B 2025 Q3: $1.8B
Q3 2025
2025 Q4: $1.9B, +8.1% QoQ 2025 Q4: $1.9B, +8.1% QoQ
Q4
2026 Q1: $2.1B, +9.4% QoQ 2026 Q1: $2.1B, +9.4% QoQ
Q1 2026
2026 Q2: $1.6B, −22.1% QoQ 2026 Q2: $1.6B, −22.1% QoQ
Q2

Latest book

2026 Q2 2026 Q1, filed 3 Aug, long equity only

Download CSV Download Excel All activity
RCUS, Arcus Biosciences 58.76% Hold 31,424,760 $30.83 $969M — —
LKFT, Lakefront Biotherapeutics 30.34% Hold 16,707,477 $29.94 $500M — —
ASMB, Assembly Biosciences 8.30%, was 5.90% Add +10.5% 4,977,089 $27.48 $137M +471,698 +$12M
Kyverna Therapeutics 2.23% Hold 4,126,119 $8.91 $37M — —
Xilio Therapeutics 0.38% Hold 650,389 $9.58 $6.2M — —

Exits / last held

Gone since 2026 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
ACLX, Arcellx 36.44% Exit 0 $114.82 $772M −6,720,803 −$772M

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2026 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

4 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 5 $1.6B −22.1% 13F-HR 8/3/2026 000112329226001034
2026 Q1 6 $2.1B +9.4% 13F-HR 5/8/2026 000112329226000642
2025 Q4 6 $1.9B +8.1% 13F-HR 2/12/2026 000112329226000164
2025 Q3 9 $1.8B — 13F-HR 11/13/2025 000112329225000642

About

Gilead Sciences, Inc.

4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

SEC filing name
GILEAD SCIENCES, INC.
Location
Foster City, CA
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf